BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provôt F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Châtelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Frémeaux-Bacchi V. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 2021;137:2438-49. [PMID: 33270832 DOI: 10.1182/blood.2020009280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Bouwmeester RN, van de Kar NCAJ, Wetzels JFM. Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome. Kidney Int 2021;100:265-8. [PMID: 33675845 DOI: 10.1016/j.kint.2021.02.033] [Reference Citation Analysis]
2 Legendre C, Rebecca-Sberro-Soussan, Zuber J. Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. Kidney Int Rep 2021;6:1489-91. [PMID: 34169186 DOI: 10.1016/j.ekir.2021.04.036] [Reference Citation Analysis]
3 Prével R, Delmas Y, Guillotin V, Gruson D, Rivière E. Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes. J Clin Med 2022;11:790. [PMID: 35160242 DOI: 10.3390/jcm11030790] [Reference Citation Analysis]
4 Brodsky RA. Eculizumab and aHUS: to stop or not. Blood 2021;137:2419-20. [PMID: 33956069 DOI: 10.1182/blood.2020010234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Alhabhbeh A, Fatima Z, Thomas A, Cook C. Rare Presentation of Atypical Hemolytic Uremic Syndrome in an Adult. Cureus 2021;13:e18184. [PMID: 34589371 DOI: 10.7759/cureus.18184] [Reference Citation Analysis]
6 Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, Yuan X, Sperati CJ, Moliterno AR, Brodsky RA. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv 2021;5:1504-12. [PMID: 33683339 DOI: 10.1182/bloodadvances.2020003175] [Reference Citation Analysis]
7 Wu X, Szarzanowicz A, Garba A, Schaefer B, Waz WR. Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review. Cureus 2021;13:e19476. [PMID: 34912617 DOI: 10.7759/cureus.19476] [Reference Citation Analysis]
8 Gunay E, Ozan M, Kaya S, Ocal E, Kutlu Z, Senol A, Danis R, Baysal E, Kalin BS, Dincyurek HD, Demir C. Pregnancy-related atypical hemolytic uremic syndrome with renal, cardiac and obstetric complications and a satisfactory recovery: a case report. Ren Fail 2021;43:460-2. [PMID: 33657972 DOI: 10.1080/0886022X.2021.1893187] [Reference Citation Analysis]
9 Milon V, Fage N, Guibert F, Frémeaux-Bacchi V, Augusto JF, Brilland B. Thrombotic microangiopathy with mild renal involvement and profound thrombocytopenia: not all roads lead to thrombotic thrombocytopenic purpura. J Nephrol 2022. [PMID: 35318588 DOI: 10.1007/s40620-022-01289-x] [Reference Citation Analysis]
10 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nga HS, Palma LMP, Ernandes Neto M, Fernandes-Charpiot IMM, Garcia VD, Kist R, Miranda SMC, Macedo de Souza PA, Pereira GM Jr, de Andrade LGM. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort. PLoS One 2021;16:e0258319. [PMID: 34748552 DOI: 10.1371/journal.pone.0258319] [Reference Citation Analysis]
12 Venier LM, Patriquin CJ, Warkentin TE. Acute thrombocytopenia suggesting thrombotic microangiopathy. Am J Hematol 2022;97:659-65. [PMID: 35253925 DOI: 10.1002/ajh.26515] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Baskin E, Fidan K, Gulhan B, Gulleroglu K, Canpolat N, Yilmaz A, Parmakiz G, Ozcakar BZ, Ozaltin F, Soylemezoglu O. Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study. J Nephrol. [DOI: 10.1007/s40620-021-01212-w] [Reference Citation Analysis]
14 Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol 2022. [PMID: 35041041 DOI: 10.1007/s00467-021-05370-8] [Reference Citation Analysis]
15 Li Q, Kong X, Tian M, Wang J, Yang Z, Yu L, Liu S, Wang C, Wang X, Sun S. Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases. Ren Fail 2022;44:1061-9. [PMID: 35730179 DOI: 10.1080/0886022X.2022.2089167] [Reference Citation Analysis]